Introduction
The p53 protein is a potent and well-characterized suppressor of tumor formation (Levine et al., 1991; Michael and Oren, 2002; Vousden and Lu, 2002) . Under normal conditions, inactive p53 protein is maintained at low levels, primarily in the cytoplasm. High levels of activated and stabilized p53 protein accumulate in the nucleus in response to various forms of cell stress, including DNA damage (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Fritsche et al., 1993; Hall et al., 1993) . Activation of endogenous p53 will induce cell cycle arrest and/or apoptosis, depending on the severity and duration of the stress. One paradigm of p53 function asserts that p53-dependent cell cycle arrest or apoptosis acts to minimize the accumulation of deleterious mutations that could eventually contribute to a malignant phenotype (Lane, 1992) . It is estimated that over 50% of cancers have acquired p53 gene mutations, ostensibly allowing the tumors to bypass this p53 checkpoint (Hollstein et al., 1991 (Hollstein et al., , 1994 . Apoptosis induction appears to be critical for the protein's tumor suppressor function. Several investigators have demonstrated that specific tumor-derived mutants have lost the ability to induce apoptosis when expressed (Friedlander et al., 1996; Ludwig et al., 1996) .
The p53 protein possesses a central, sequence-specific DNA binding domain and an amino-terminal transactivation domain (Levine, 1997) . The ability of p53 to transactivate target genes is critical for normal p53 function. For example, p53 regulates cell cycle arrest through transactivation of the cyclin-dependent kinase inhibitor p21 waf1/cip1/sdi1 (el-Deiry et al., 1993 (el-Deiry et al., , 1994 . Additionally, several lines of evidence imply a requirement for nascent gene transcription during p53-dependent apoptosis. First, the use of transcription and translation inhibitors can prevent p53-dependent apoptosis in some cases (Polyak et al., 1997) . Second, p53 can directly transactivate several genes that have an established role in apoptosis. These genes include CD95, p53AIP1, bax, noxa, DR5 and apaf 1 (Miyashita and Reed, 1995; Oda et al., 2000a, b; Sheikh and Fornace, 2000; Robles et al., 2001) . Further, 90% of all p53 mutations in human tumors occur within the protein's central DNA binding domain (Hollstein et al., 1991 (Hollstein et al., , 1994 . Many of these mutant proteins have lost transcriptional regulatory activity and do not induce apoptosis when expressed (Ludwig et al., 1996) . In addition to its transactivation function, p53 can also repress the expression of specific target genes. This activity may also play an important role in p53-dependent apoptosis. Again, several genes specifically repressed by p53, including bcl-2, survivin and MAP4, have an established role in apoptosis (Miyashita et al., 1994; Murphy et al., 1996; Mirza et al., 2002) .
Inappropriate expression of the bcl-2 proto-oncogene is observed in many tumor types and contributes to multistep tumorigenesis by enhancing cell survival (McDonnell and Korsmeyer, 1991; Beham et al., 1998; Rodriguez-Villanueva et al., 1998; Bruckheimer et al., 2000) . Bcl-2 efficiently blocks cell death induced by diverse apoptotic stimuli, including endogenous p53 activation or following p53 gene transfer Adams and Cory, 1998; Schumacher et al., 2001) . A common, but not exclusive, feature of bcl-2 function is the ability to modulate mitochondrial permeability following cell stress (Adams and Cory, 1998) . The mitochondrial pathway to caspase activation has also been implicated in p53-induced apoptosis. For example, the proapoptotic p53 target genes bax, noxa and p53AIP1 localize to mitochondria (Miyashita and Reed, 1995; Oda et al., 2000a, b) . Also, expression of wild-type (wt) p53 leads to cytochrome c release from mitochondria and processing of procaspase 9 (Schuler et al., 2000) . Additional experiments demonstrate that apaf-1 and caspase 9 are required for p53-dependent apoptosis in some cell types (Soengas et al., 1999) .
Other possible mechanisms for bcl-2-mediated resistance to p53-induced apoptosis exist. We and others have previously shown that bcl-2 can inhibit p53-dependent transactivation of p53-responsive promoters Froesch et al., 1999) . Furthermore, in WMN and MCF7 cells exposed to genotoxic stress, bcl-2 can inhibit the expression of endogenous p53 target genes (Froesch et al., 1999; Zhan et al., 1999) . Finally, as reported in HeLa and SAOS2 cells, bcl-2 can alleviate p53-mediated transcriptional repression (Shen and Shenk, 1994) . Based on these observations, it was of interest to utilize a comprehensive, unbiased approach to further characterize the transcriptional response of p53 and to what extent it may be modulated by the presence of bcl-2.
Results

Adenovirus-p53 infection of vector control and bcl-2-overexpressing cells
Stable vector control (PC3-BN) and bcl-2-overexpressing clones (PC3-Bcl-2) were generated from parental PC3 prostate cancer cells (Beham et al., , 1998 Herrmann et al., 1997 Herrmann et al., , 1998 Schumacher et al., 2001; Honda et al., 2002) . Western blot analysis confirmed that PC3-Bcl-2 cells express significantly more bcl-2 protein than control PC3-BN cells (data not shown) (Munshi et al., 2001) . Before initiating the expression profiling studies, it was important to identify virus treatment parameters that provided for efficient and equal infection of both cell lines and to establish that significant protection against Ad-p53-induced cell death was conferred by bcl-2. Virus infection efficiency was assayed in each cell line using an adenovirus expressing green fluorescent protein (Ad-GFP). Cells were infected at various vector doses from 0 to 1500 total viral particles per cell (vp/c). This corresponded to approximately 0-20 infectious particles per cell. Hereafter, adenoviral vector doses are reported in total viral particles per cell. GFP-positive cells were detected and counted by flow cytometry 48 h after infection. Using vector dose of 1000 vp/c, both cell lines achieve at least a 90% infection rate (data not shown).
The kinetics of p53 protein expression was assayed by Western blot in each cell line after infection with Ad-p53 and Ad-LacZ (1000 vp/c). PC3 cells do not express endogenous p53 protein due to a gross deletion of one allele and a single base-pair deletion in the remaining allele (Isaacs et al., 1991; Rubin et al., 1991; Carroll et al., 1993) . As expected, p53 protein expression was not detected at any time point after control virus infection (data not shown). Western blot analysis demonstrates that p53 protein expression occurs in both cell lines, with similar kinetics, after Ad-53 treatment ( Figure 1a ). Adenovirus-mediated p53 expression can be detected as early as 6 h post infection. High levels of p53 protein are still evident at 24 h post infection.
A dose-response analysis was performed by measuring cell viability 96 h after Ad-p53 infection. After Adp53 infection, at 0-2000 vp/c, PC3-BN cells exhibited a dose-dependent decrease in cell viability (data not shown). Importantly, bcl-2 provided significant protection against Ad-p53-mediated cell death at each dose (Po0.01, o0.00001, o0.00001 and o0.001 for vector doses 250, 500, 1000 and 2000 vp/c, respectively). The protective effect of bcl-2 was most evident at 1000 vp/c. Based on this result, along with infection efficiency and p53 expression data, 1000 vp/c was chosen for further study.
Ad-p53-induced cell death was examined in PC3-BN and PC3-Bcl-2 cells over a 96 h time course (Figure 1b) . Ad-LacZ control virus infection resulted in little or no loss of cell viability throughout the time course. Additionally, no cell death was detected at 24 h after Ad-p53 infection. At 48, 72 and 96 h post infection, bcl-2 provided significant protection against Ad-p53 treatment compared to PC3-BN cells (Po0.01, o0.001, o0.01, respectively). DNA content measurements were performed to help verify that the observed loss of viability was due to apoptosis. PC3-BN and PC3-Bcl-2 cells were again treated with Ad-LacZ or Ad-p53 (1000 vp/c). DNA content was measured at 0, 24, 48 and 72 h post infection by flow cytometry after staining with propidium iodide (Figure 1c ). Cells with a subdiploid DNA content were scored as apoptotic. The results are consistent with previous trypan blue assay results. Ad-LacZ treatment did not result in the induction of apoptosis. Similarly, at 24 h, there is no apoptosis evident after Ad-p53 treatment. At later time points, bcl-2 provides significant protection against Ad-p53-mediated apoptosis.
cDNA array hybridization and data analysis High-density cDNA arrays were used to identify genes displaying differential expression following Ad-p53 gene transfer in PC3-BN and PC3-Bcl-2 cells. RNA was harvested 24 h after Ad-LacZ or Ad-p53 infection (1000 vp/c). This time point was chosen based on the temporal relationship between p53 expression and detection of apoptosis (Figure 1a-c) . For each cell line, control virus treatments were compared to Ad-p53 treatments to identify p53-responsive genes. Hybridizations were performed in duplicate from independent RNA extractions. The raw data from each hybridization were normalized, background corrected and analysed as described in Materials and methods.
A total of 40 transcripts were identified that were significantly upregulated in both PC3-BN and PC3-Bcl-2 cells after Ad-p53 treatment (Table 1) . Reassuringly, p53 itself was identified as the transcript exhibiting the most significant increase after Ad-p53 treatment. Of these transcripts, 12 were expressed sequence tags (est's), and six were known p53-responsive genes (caveolin-1, cyclin G1, PIG 11, PAI-1, cytoplasmic FMR1 interacting protein 2 and p53-responsive gene 5). Conversely, a total of 19 transcripts (12 est's and seven known genes) exhibited significant downregulation in both PC3-BN and PC3-Bcl-2 cells following Ad-p53 gene transfer (Table 2 ). In each case, these est's represent candidate novel p53 target genes. To assess the reliability of these data, several genes, including three uncharacterized est's, were chosen for verification by Northern blot analysis (Figure 2a and b) . We are referring to the est's transactivated in response to p53 expression as pat-1 and pat-2 (for p53 activated transcripts 1 and 2). Similarly, the est repressed after Ad-p53 infection is referred to as prt-1 (p53 repressed transcript 1). In each case, the Northern blot data are in concordance with the array data analysis.
The above data indicate that bcl-2 does not uniformly abrogate the ability of p53 to regulate gene transcription. However, 15 genes were identified that were significantly up-or downregulated in PC3-BN cells relative to PC3-Bcl-2 cells after p53 gene transfer (Table 3 ). Northern blot analysis shows that both the proteasome 26S subunit 2 (PSMD2) and SOD-1 are downregulated in PC3-BN cells but are, at best, modestly repressed in PC3-Bcl-2 cells (Figure 2c ). However, when normalized to 18S, SOD-1 was downregulated 1.5-fold in PC3-BN cells and 1.2-fold in PC3-Bcl-2 cells. Similarly, PSMD2 was down regulated 1.4-fold in PC3-BN cells and 1.1-fold in PC3-Bcl-2 cells. Additional quantitative analysis is needed to determine if there is a statistically significant difference in the p53 response of SOD-1 and PSMD2 in control versus bcl-2-overexpressing PC3 cells. Still, these findings suggest that bcl-2 may be one determinant of target gene responsiveness to p53 expression.
Examination of additional p53 target genes that mediate apoptosis
The above cDNA array experiments allowed us to identify a large number of p53-responsive genes, a subset of which was influenced by bcl-2 overexpression. However, several additional p53 targets of interest were present on the arrays, but did not display significant changes in transcript level using the statistical methodologies we employed. To investigate such genes, probes for bax, MDM2, PIG3 and survivin were generated and used for Northern blot analysis. The mRNA level of these genes was measured in untreated Ad-LacZ, and Ad-p53-treated cells after 24 h (Figure 3 ). Bax showed an equal induction in both cell lines 24 h after Ad-p53 infection. However, the remaining genes displayed a different response in PC3-Bcl-2 cells compared to control cells. For example, the induction However, PC3-Bcl-2 cells exhibited higher levels of survivin mRNA compared to PC3-BN cells. All of these genes are clearly modulated in response to p53 expression. Therefore, each represents a false negative result in our array analysis. One difficulty encountered with our cDNA array platform was the problem of signal Figure 2 Verification of cDNA array data by Northern blot analysis. Cells were treated with Ad-p53 and Ad-LacZ, or not treated. Northern blots were prepared using RNA harvested 24 h after infection. A probe for 18S RNA was used to demonstrate equal loading. (a) Several genes (Table 1) were identified by array analysis that displayed an upregulation in both cell lines after p53 expression. Select genes were chosen for verification. Pat-1 and pat-2 (p53 activated transcripts 1 and 2) are uncharacterized est's. (b) Genes were identified as being downregulated in both cell lines after p53 expression ( Table 2 ). The expression of prt-1 (p53 repressed transcript 1), also an uncharacterized est, was verified by Northern blot analysis. (c) Verification of genes displaying an altered response to p53 expression in PC3-BN versus PC3-Bcl-2 cells (Table 3 ) Array data analysis identified genes responding to p53 expression in PC3-BN cells with no change of transcript level in PC3-Bcl-2 cells. Genes with a ''m'' in the ''control/bcl-2'' column were upregulated in PC3-BN cells after Ad-p53 treatment with no change in PC3-Bcl-2 cells. Conversely, genes with a ''k'' were downregulated in PC3-BN cells after Ad-p53 treatment with no change in PC3-Bcl-2 cells bleeding. MDM2, bax and PIG3 were each spotted next to a cDNA that gave an intense signal that ''bled'' into the area of adjacent spots. As this does not occur in the same way for each hybridization, the signal intensities for MDM2, PIG3 and bax varied widely on repeat hybridizations. This variation prevented these genes from achieving a significant score in our statistical analysis.
Differential expression of select p53-responsive genes in LNCaP-BN and LNCaP-Bcl-2 cells following etoposide treatment
Several p53-responsive genes show an altered transcriptional response to Ad-p53 gene transfer in control versus bcl-2-overexpressing PC3 cells. It was of interest to determine if this altered response could also be observed after activation of endogenous wt p53. The LNCaP prostate carcinoma cell line, which is wt for p53, was used to generate vector control (LNCaP-BN) and bcl-2-overexpressing (LNCaP-Bcl-2) clones (Beham et al., , 1998 Herrmann et al., 1997 Herrmann et al., , 1998 Munshi et al., 2001; Schumacher et al., 2001; Honda et al., 2002) . Both cell lines were treated with increasing concentrations of the topoisomerase 2 inhibitor etoposide. Following treatment, p53 protein accumulated to equal levels and with identical kinetics in LNCaP-BN and LNCaP-Bcl-2 cells (Figure 4a ). Bcl-2 provided significant protection against etoposide-induced cell death (Figure 4b ). Based on these results, LNCaP-BN and LNCaP-Bcl-2 cells were treated with 10 mg/ml etoposide and RNA was harvested over a 24 h time course. Genes that displayed an altered response to Ad-p53 in control versus bcl-2-overexpressing PC3 cells were tested for a differential response in LNCaP-BN and LNCaP-Bcl-2 cells following etoposide treatment. Consistent with our previous data, MDM2 mRNA increased sooner and to greater levels in LNCaP-Bcl-2 cells compared to control cells ( Figure 5 ). Similarly, PIG3 mRNA was again induced to higher levels in vector control cells compared to bcl-2-overexpressing cells. A downregulation of PSMD2 mRNA occurs in both LNCaP-BN and LNCaP-Bcl-2 cells, however, it appeared to be less robust in LNCaP-Bcl-2 cells.
Discussion
Alterations in p53 are among the most common molecular events that occur during multistep carcinogenesis (Hollstein et al., 1994 (Hollstein et al., , 1991 . Typically these alterations result in loss of p53 function (Friedlander et al., 1996; Ludwig et al., 1996) . Additionally, there is accumulating evidence that alterations in p53 may be predictive of therapeutic response or clinical outcome in Figure 3 Northern blot analysis of additional p53 target genes. Additional p53 target genes were analysed for a differential response to p53 expression in PC3-BN versus PC3-Bcl-2 cells. Northern blot analysis was again performed 24 h after infection with Ad-p53, Ad-LacZ or no treatment. Northern blots were generated and hybridized as described patients with specific types of cancer (Kovach et al., 1996; Lowe, 1999; Pirollo et al., 2000) . In this regard it is noteworthy that p53 is among the principal mediators of the response to genotoxic stress and that many cancer therapeutic interventions, including ionizing radiation and chemotherapy, are predicated on the selective induction of genotoxic stress in cancer cells. Importantly, the feasibility of restoration of p53 function using adenoviral-mediated wt p53 gene transfer (Ad-p53) is currently being evaluated in clinical trials for patients with carcinoma of the lung (Swisher and Roth, 2002) , prostate (Introgen, 2003) , urinary bladder (Pagliaro, 2000) , brain (Lang et al., 2003) , breast (Dummer et al., 2000) , ovary (Wen et al., 2003) , and head and neck (Clayman et al., 1998 (Clayman et al., , 1999 . Upregulation of the antiapoptotic bcl-2 proto-oncogene is a common event in diverse malignancies including prostate cancer (MacCarthy-Morrogh et al., 1999; Moul, 1999) . Many studies have established that bcl-2 can protect against cell death resulting from genotoxic stress in general and p53 activation specifically Adams and Cory, 1998; Schumacher et al., 2001) . Additionally, recent findings suggest that bcl-2 levels in tumor cells may provide important predictive information in cancer patients (Mano et al., 1999; Pollack et al., 2003) . Understanding the clinically relevant molecular variables that are likely to influence p53 function, including upregulation of the anti-apoptotic bcl-2 oncoprotein, will facilitate the ultimate success of these trials. The activation of p53 in response to diverse cell stresses, including hypoxia and DNA damage, can mediate several outcomes including cell cycle arrest, differentiation and apoptosis. The p53-dependent transcriptional regulation of target gene expression is critical for mediating these outcomes. Although there are notable examples of p53 function being mediated by transcription-independent mechanisms (Caelles et al., 1994; Wagner et al., 1994; Haupt et al., 1995; Ding et al., 2000; Schuler and Green, 2001; Mihara et al., 2003) , much has been learned about the molecular mediators of the response to DNA damage from the characterization of genes transcriptionally regulated by p53. On the basis of probability estimates, there are literally thousands of gene promoters that could possess a p53 DNA binding element, although these likely will not all represent legitimate p53-regulated targets. With the above issues in mind, it was of interest to apply an expression profiling strategy to assess comprehensively genes that exhibit alterations in transcript level following Ad-p53 gene transfer and if this response could be modulated by bcl-2.
The majority of p53-responsive genes identified in our study are not among the known and rigorously verified p53 transcriptionally regulated targets. Therefore, we attempted to identify whether any of these genes possessed canonical p53 DNA binding elements. Wang et al. (2001) used publicly available genomic sequence data and bioinformatic techniques to perform a genomewide search for p53 DNA binding sites. The complete list of the 4852 genes is available online through a link to the JBC website (http://www.jbc.org) as supplemental data for the Wang reference (Wang et al., 2001) . A second algorithm has been developed to identify putative p53 DNA binding sites, p53MH, and is also available online (http://linkage.rockefeller.edu/p53) (Hoh et al., 2002) . The p53MH database lists 2583 human gene entries and 1713 mouse orthologs. We compared our cohort of p53-responsive genes against these p53 target databases. While this approach is useful for identifying candidate p53-responsive genes, it must also be appreciated that all confirmed p53 response elements do not conform exactly to the p53 DNA binding site consensus sequence. Further, of the known p53 target genes identified by our analysis, only PAI-1, PIG11 and cyclin G1 were correctly identified using these databases. Despite these limitations, approximately half of the genes identified by our analysis possessed at least one candidate p53 DNA binding site in the corresponding promoter regions. These findings, while not definitive, at least are consistent with the concept that a subset of modulated genes identified following Ad-p53 gene transfer will be confirmed as p53 targets using standard promoter analysis methodologies.
Instead of simply identifying genes with a twofold or greater change in expression between treatments, our analysis took into account the mean expression of each gene across all hybridizations as well as variation among repeat hybridizations. Using such a rigorous approach minimizes the presence of false positives yet increases the likelihood of ''false negatives'', that is, genes modulated by p53 that are not identified in the analysis. Although a large number of cDNAs were screened, the statistical methodologies described and used here produced a data set that is manageable and highly reliable. As expected, the majority of genes identified as p53-responsive in our analysis exhibited equivalent levels of expression in PC3-BN and PC3-Bcl-2 cells. Figure 5 Northern blot analysis of p53-responsive genes in LNCaP-BN and LNCaP-Bcl-2 cells after etoposide treatment (10 mg/ml). After treatment, RNA was harvested over a 24 h time course. Northern blots were generated and hybridized to probes for the genes indicated Assessment of p53-responsive genes in the context of bcl-2 KB Spurgers et al Interestingly, five of the seven known genes repressed in both cell lines following Ad-p53 gene transfer have been shown to function as regulators of cell cycle progression or checkpoint response. In eukaryotic cells there exists a two-wave G1 checkpoint response (Bartek and Lukas, 2001b) . For example, in response to DNA damage, there is a rapid, p53-independent, degradation of the cdc25a phosphatase resulting in cell cycle arrest (Mailand et al., 2000; Bartek and Lukas, 2001a) . Cdc25a functions to activate cyclin E-cdk2 complexes, which are critical for the G1/S transition. The ''second wave'' of the G1 checkpoint response involves the p53-dependent transactivation of the cdk inhibitor p21
waf1/cip1/sdi1
. Importantly, our data suggest that a p53-dependent transcriptional repression of cdc25a, and other genes, could also participate in this second-wave maintenance of cell cycle arrest.
There were several genes that exhibited a differential response in vector control cells compared to bcl-2-expressing cells following Ad-p53 gene transfer. These include genes that were transactivated as well as genes that were repressed following Ad-p53 treatment. Through cDNA array analysis, SOD-1 and PSMD2 showed significant reductions in PC3-BN cells compared to PC3-Bcl-2 cells following Ad-p53 gene transfer. Northern blot analysis revealed a similar pattern of expression for these genes following Ad-p53 treatment. Further quantitative analysis is needed to determine if there is a statistically significant difference in the p53 response of SOD-1 and PSMD2 in control versus bcl-2-overexpressing PC3 cells. The copper/zinc superoxide dismutase (sod-1) enzyme catalyses the dismutation of superoxide to hydrogen peroxide and oxygen (Fridovich, 1986) . A decrease in SOD-1 activity can result in an increase in H 2 O 2 levels and increased sensitivity to oxidative stress (Huang et al., 2000) . Downregulation of SOD-1 mRNA or protein activity has been shown to induce apoptosis in human leukemia and PC12 cells (Troy and Shelanski, 1994) . We speculate that a downregulation of SOD-1 by p53 could contribute to the production of oxidative stress and sensitize cells to apoptosis. Thus, inhibiting the downregulation of SOD-1 could represent a significant bcl-2-mediated protective mechanism against p53-induced apoptosis. Expression of the regulatory, noncatalytic subunit 2 of the 26S proteasome (PSMD2) (Tanaka and Tsurumi, 1997) was also shown to be more significantly downregulated after Ad-p53 infection of PC3-BN cells compared to PC3-Bcl-2 cells. This gene is also known as TRAP2, and has been shown to interact with the intracellular domain of the p55 TNF receptor (Boldin et al., 1995) . To our knowledge, PSMD2 has not been reported to be p53 regulated although the 26S proteasome has an established role in apoptosis and p53 turnover (Naujokat and Hoffmann, 2002) .
Similarly, survivin shows a pattern of p53-dependent gene regulation in control and bcl-2-overexpressing cells similar to that of SOD-1 and PSMD2. Survivin is an inhibitor of apoptosis (IAP) family member that binds to and inhibits caspases. This gene has been identified as a p53 target and plays a role in p53-induced apoptosis (Hoffman et al., 2002; Mirza et al., 2002) . Importantly, downregulation of survivin mRNA using antisense oligos can induce apoptosis (Chen et al., 2000; Olie et al., 2000) . We speculate that the maintenance of higher survivin mRNA levels in PC3-Bcl-2 cells, compared to control cells, contributes to the observed resistance to Ad-p53-induced cell death.
After Ad-p53 treatment, we observed mdm2 mRNA to be induced to significantly higher levels in PC3-Bcl-2 cells compared to control cells. The mdm2 oncoprotein is a direct p53 target gene and a critical negative regulator of p53 function (Momand et al., 1992; Honda et al., 1997) . This observation suggests that bcl-2 may enhance the negative autoregulation of p53 function. Conversely, PIG3 was induced to higher levels in control cells compared to PC3-Bcl-2 cells after Ad-p53 gene transfer. PIG3 was originally identified using serial analysis of gene expression (SAGE) to identify p53-responsive genes (Polyak et al., 1997) . PIG3 is related to an oxidoreductase and is implicated in the generation of the oxidative stress that is observed during p53-induced apoptosis. These observations are of interest in that bcl-2 has previously been consistently shown to protect against cell death induction resulting from oxidative stress (Voehringer, 1999; Voehringer and Meyn, 2000; Amstad et al., 2001; Chen et al., 2003) .
It was of interest to determine if the altered response of these select genes could also be observed after activation of endogenous wt p53 in the context of bcl-2 overexpression. Most strikingly, and consistent with our observations in the PC3 cell line, mdm2 and PIG3 show distinct expression patterns in LNCaP-BN versus LNCaP-Bcl-2 cells after etoposide treatment. The induction of these two genes in LNCaP cells following etoposide treatment is likely, at least partly, p53 dependent, as these transcriptional changes do not take place in the p53 null PC3 cell line after etoposide treatment (data not shown). Together, these findings are consistent with previous studies demonstrating that bcl-2 overexpression can prevent the induction of specific p53 target genes after DNA damage (Froesch et al., 1999; Zhan et al., 1999) . Likewise, it has been previously demonstrated that bcl-2 can influence p53-mediated transcriptional repression even when p53-dependent transactivation is not affected (Shen and Shenk, 1994) . The biologic and clinical significance of the differential regulation of these p53-responsive genes in mediating bcl-2 cell death protection is being assessed in ongoing investigations. Importantly, although beyond the scope of the current study, it is of interest to establish the extent of correlation between validated transcript levels and modulations in steady-state levels of the corresponding proteins.
There are several possible mechanisms by which bcl-2 could affect p53 function. First, p53 is phosphorylated on multiple residues in response to various forms of cell stress (Jayaraman and Prives, 1999) . Significantly, different forms of genotoxic stress can result is distinct phosphorylation patterns of the p53 protein and divergent patterns of p53-dependent target gene activation (Zhao et al., 2000) . Based on these observations, it will be of interest to determine if bcl-2 overexpression can influence the phosphorylation pattern of p53.
It has previously been reported that the intracellular redox environment can regulate p53 function (Jayaraman and Prives, 1999) and that p53 requires a reduced state for optimal DNA binding (Hainaut and Milner, 1993; Rainwater et al., 1995; Pearson and Merrill, 1998; Buzek et al., 2002) . In this regard, it may be relevant that bcl-2 overexpression is associated with an increase in total cellular GSH level (Mirkovic et al., 1997) . This suggests that a reducing environment is important for bcl-2-mediated resistance to apoptosis. Forced depletion of GSH from bcl-2-overexpressing cells sensitizes these cells to apoptotic stimuli. Furthermore, treatment with the antioxidant N-acetylcysteine can mimic the protective effect of bcl-2 overexpression. Importantly, subsequent studies demonstrate that induced bcl-2 overexpression can cause a redistribution of GSH from the cytosol to the nucleus (Voehringer et al., 1998) . We thus speculate that bcl-2 can alter the redox environment of the nucleus and in this way may affect p53 function.
In summary, our understanding of the mechanistic basis of diverse cellular processes, including cell division, differentiation and cell death, has been greatly augmented by the analysis of the p53 tumor suppressor gene. There is abundant evidence that the mechanistic basis of p53 function is in large measure determined by the transactivation and transrepression of target gene expression. Arguably, we know a relatively large amount about comparatively few of the genes that p53 likely regulates. It can be anticipated that further characterization of new p53 transcriptionally regulated target genes will greatly expand our understanding of multistep carcinogenesis and thereapeutic response.
Materials and methods
Cell lines and cell culture
The PC3 and LNCaP prostate carcinoma cell lines have been described (Kaighn et al., 1979; Horoszewicz et al., 1983) . Parental cells were obtained from the American Type Culture Collection (Rockville, MD, USA). A 1.8 kb fragment of the Bcl-2 cDNA containing the open reading frame was cloned into an expression plasmid (pSFFV-neo). Stable empty vector control cells and bcl-2-overexpressing clones were generated using standard gene transfer techniques and selection in Geneticin (Invitrogen, Carlsbad, CA, USA) and have been previously described in detail (Beham et al., , 1998 Herrmann et al., 1997 Herrmann et al., , 1998 Munshi et al., 2001; Schumacher et al., 2001; Honda et al., 2002) . Cell lines were cultured at 371C in a humidified chamber under 5% CO 2 using RPMI 1640 media (Invitrogen) supplemented with 10% FBS, 100 U penicillin and 100 mg/ml streptomycin. LNCaP cells were treated with etoposide (Sigma, St Louis, MO, USA) dissolved in dimethyl sulfoxide (DMSO) added directly to the complete media of monolayer cultures.
Adenovirus infections
All adenoviruses used in this study were maintained by the vector core facility of the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Construction of the recombinant, replication-deficient, type 5 adenovirus expressing human p53 (Ad-p53) has been described (Zhang et al., 1994 (Zhang et al., , 1995 . Virus expressing b-galactosidase (Ad-LacZ) was used for control infections. Viral titers were determined using optical density (OD) measurements. For all infections, cells were seeded to reach 50-75% confluence in 48 h. On the day of infection, two plates for each cell line were counted to obtain accurate cell number information. Viral stocks were diluted in serum-free media and added directly to the fresh, complete media of monolayer cultures. The volume of media was altered to keep the concentration of virus constant across experiments. To determine infection efficiency, infections were performed with an adenovirus expressing green fluorescent protein (Ad-GFP).
Cell viability assays
Cells were treated with Ad-LacZ and Ad-p53 and analysed at 0, 24, 48, 72 and 96 h. At 24 h, all wells were fed with fresh complete media. Floating and adherent cells were collected by trypsination and resuspended in PBS. An aliquot of the cell suspension was diluted 1 : 2 with a 0.4% solution of trypan blue (Sigma). Blue cells (nonviable) and nonstaining viable cells were counted and recorded using a hemacytometer (Hausser Scientific, Horsham, PA, USA).
DNA content measurements
Cells were harvested with trypsin and then fixed in 10 ml of cold 70% ethanol at 0, 24, 48 and 72 h. Cells were stored in 70% ethanol at À201C for 2-14 days. Fixed cells were washed once in PBS and resuspended in DNA staining solution (40 mg/ ml propidium iodide and 20 mg/ml RNase A (Sigma) in PBS). Cells were then incubated at 371C for 20 min. FL2 fluorescence was measured on a Becton-Dickinson FACScalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Cells with a sub-G0/G1 DNA content were scored as apoptotic.
RNA isolation and cDNA array hybridizations
RNA was harvested 24 h following viral gene transfer. After washing plates once with PBS, 4 ml of Trizol reagent (Invitrogen) was added directly to each 100 mm plate. Cells were scraped and transferred to 1.5 ml centrifuge tubes and processed for total RNA following the manufacturer's instructions. Using the GeneFilters protocol (Invitrogen), 7 mg of total RNA was used to generate 33 P-labeled, first strand cDNA probes for array hybridization. The cDNA arrays used were the Human GeneFilters (releases I-VII from Invitrogen). Each of the seven arrays used is spotted with 5184 cDNAs. Some redundancy and overlap do exist between arrays. Array hybridizations were carried out according to the Invitrogen protocol. After the recommended washes, blots were rinsed in 2 Â SSC, placed on moist Whatman paper and wrapped in plastic wrap. Membranes were exposed to a storage phosphor screen for 24-48 h and the images then captured using a Storm phosphor imager (Amersham Biosciences, Piscataway, NJ, USA). Raw intensity data for each spot on the array was obtained using ArrayVision software (Imaging Research Inc., Ontario, Canada) .
Array data analysis
Raw intensity values for each spot were background corrected by subtracting the median background value of all spots on the array. Each array was multiplicatively normalized by setting the 75th percentile of 'reliable spots' on the array to 1000. Reliability was defined as those spots with intensity values exceeding the 97.5th percentile of blank spots on arrays. Finally, a base 2 log transformation was applied.
For each gene, G, on the microarray, we used a linear model to predict the observed value, Y ijkl , of the log-transformed normalized expression level of G in each replicate experiment(l ¼ 1,2) for each cell line (j ¼ 1,2) with each treatment (k ¼ 1,2). The model took the form
Here m is the overall mean expression of G. The term m estimates changes in mean expression attributable to differences between cell lines (vector control or bcl-2-expressing). The term b k estimates changes in mean expression attributable to differences between treatments (Ad-p53 or Ad-LacZ). The interaction terms (ab) jk estimate treatment-dependent changes in expression that occur in one cell line but not the other. The term e jkl accounts for all unexplained random variation; this is assumed to be normally distributed with mean 0 and a genespecific standard deviation s.
All parameters were assumed to be random variables with uninformative prior distributions. Using the linear model, the observed gene expression levels were used to update the prior distributions and to form posterior probability estimates of the fold change (FC). For each effect of interest, we calculated the posterior probability that FC exceeded 2. For example, the posterior probability that FC attributable to differences in treatment exceeded 2 was computed on the log scale as Pðb 2 41jDataÞ À Pðb 2 Àb b 2 Þ=S b 4ð1 Àb b 2 Þ=S b jDataÞ whereb b 2 and S b are the least-square estimates of the treatment effect and its standard error, respectively. We selected genes with at least a 95% posterior probability of a cell line effect, treatment effect, or interaction effect leading to FC42. We excluded genes with an overall mean mo3.5 on the log 2 scale. Finally, for each significant gene, we examined blot images to ensure that the signals were not due to artifacts or errors in image alignment.
Northern blot analysis
Viral infections and RNA isolation were carried out as described above. For Northern blot analysis, 11-16 mg of total RNA was resolved on a 1.2% agarose, 7.4% formaldehyde gel in 1 Â MOPS buffer and then electrotransferred to a charged nylon membrane (Hybond-N þ , Amersham Biosciences) and crosslinked. In order to confirm cDNA array data, DNA clones used to spot the arrays were obtained and used to generate probes for Northern blot analysis. These clones are IMAGE/LLNL (Lennon et al., 1996) cDNA clones, sequence verified and distributed by Invitrogen. The survivin cDNA was a generous gift of Dr Maureen Murphy (Fox Chase Cancer Center, Philadelphia, PA, USA). Clone insert DNA was isolated by gel purification and labeled with [a 32 -P]dCTP (Amersham Biosciences), random hexamers and Klenow enzyme (Invitrogen). Northern blots were prehybridized at 421C for 2 h in MicroHyb solution (Invitrogen) containing 5 mg/ml human Cot-1 DNA (Invitrogen) and 100 mg/ml salmon sperm DNA (Sigma). Purified probes were added at a final concentration of 2 Â 10 6 cpm/ml and hybridized for 18 h. Washes were performed twice in 2 Â SSC, 1% SDS and once in 0.1 Â SSC, 0.1% SDS for 20 min at 551C. Images were captured using a Storm phosphorimager and ImageQuant software (Amersham Biosciences). To test for equal loading of RNA samples, membranes were probed with an antisense 18S oligo probe, 5 0 -ctgcagcaactttaatatacgctattggagctggaattacc-3 0 (Sigma-Genosys, The Woodlands, TX, USA). A total of 63 ng of this oligo was end-labeled using T4 kinase (Invitrogen) and [g 32 -P]ATP (Amersham Biosciences). After purification, this probe was hybridized to the membranes at a concentration of 4 Â 10 5 cpm/ml.
Western blot
For Western blot analysis, cells were seeded into 100 mm plates. At appropriate time points, cells were scraped into their existing media and centrifuged. Cell pellets were washed once in PBS. For cell lysis, 100-200 ml of Triton-X lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.02% Na azide, 1% Triton-X) was added to the washed cell pellets, transferred to 1.5 ml tubes and placed on ice for 4-24 h. The supernatants were cleared and collected by centrifuging at 14 000 r.p.m. for 30 min at 41C in a microcentrifuge. Samples were stored at À201C until use. Protein concentrations were determined using the Bio-Rad Protein Assay based on the Bradford method (Bradford, 1976) . A measure of 20-60 mg of protein was combined with an equal volume of 2 Â loading buffer (0.125 M Tris pH 6.8, 4% SDS, 20% glycerol, 10 mg/ml bromphenol blue, 4 M urea, 0.6 M 2-b mercaptoethanol). Samples were boiled for 5 min, then loaded and resolved on 12.5% acrylamide gels containing SDS. After electrophoresis, protein was electrotransferred to NitroPure nitrocellulose membranes (Osmonic's, Minnetonka, MN, USA). Membranes were routinely blocked and incubated with primary antibodies in PBS-T (0.5% Tween-20) with 5% nonfat dry milk. Incubation with primary antibodies was carried out as indicated below. After washing, membranes were incubated with appropriate Horseradish peroxidose-conjugated secondary antibodies for 1 h at room temperature. Immunocomplexes were detected using ECL reagents (Amersham Biosciences). The primary antibodies used are as follows: anti-p53 (Bp53-12, Santa Cruz, Santa Cruz, CA, USA), 1 : 1500; anti-Bcl2 (6C8, Pharmingen, San Diego, CA, USA) 1 : 500; anti-actin (AC-40, Sigma) 1 : 1000.
